ANG Lifesciences

What does ANG Lifesciences do?

ANG Lifesciences India Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, reporting net sales of 17 Cr and a net loss of 2 Cr for the quarter ending March 2025. The company has a market cap of Rs 39 Cr and operates from Amritsar, Punjab.

Overview:<BR>ANG Lifesciences India Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as a Private Limited Company on June 14, 2006, under the name "ANG Lifesciences India Private Limited." It converted to a Public Limited Company on March 02, 2010, before reverting to a Private Limited Company on September 22, 2010. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 17 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: -2 Cr (Quarterly Results - Mar 2025)<BR>- Market cap: Rs 39 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 1.24<BR>- Return on Equity: -19.40%<BR>- Price to Book: 0.60<BR><BR>Contact Details:<BR>Address: Darbara Complex SCO 113 I Flr, Dist. Shopping Centre B Block Amritsar Punjab : 143001<BR>Tel: 91-0183-5070118/5070119<BR>Email: cs@anglifesciences.com<BR>Website: http://www.anglifesciences.com

What is the bonus history of the ANG Lifesciences?

ANG Lifesciences has issued bonuses in recent years, including a 1:4 bonus on July 13, 2022, and a 1:1 bonus on September 22, 2021, reflecting a commitment to rewarding shareholders.

ANG Lifesciences has a notable bonus history. The most recent bonus issue was a 1:4 bonus announced on July 13, 2022, with a record date of July 14, 2022. Prior to that, the company issued a 1:1 bonus on September 22, 2021, with a record date of September 23, 2021. This indicates a pattern of rewarding shareholders through bonus shares in recent years.

Has ANG Lifesciences declared dividend?

ANG Lifesciences India Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of November 2, 2021. However, the total returns over various periods show significant losses, and the dividend yield remains at 0%.

ANG Lifesciences India Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 02 Nov 21<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -36.53%, the dividend return was 0%, resulting in a total return of -36.53%.<BR><BR>Over the past year, the price return was -43.38%, with a dividend return of 0%, leading to a total return of -43.38%.<BR><BR>In the 2-year period, the price return was -59.24%, the dividend return was 0%, culminating in a total return of -59.24%.<BR><BR>For the 3-year period, the price return was -83.81%, with a dividend return of 0%, resulting in a total return of -83.81%.<BR><BR>In the 4-year period, the price return was -56.25%, the dividend return was 1.51%, leading to a total return of -54.74%.<BR><BR>Over the last 5 years, the price return was 92.43%, the dividend return was 6.12%, resulting in a total return of 98.55%.<BR><BR>Overall, while ANG Lifesciences has declared a dividend, the total returns over various periods indicate significant losses, particularly in the shorter time frames, with a positive return only in the 5-year period. The dividend yield remains at 0%, suggesting limited income generation from dividends in the recent past.

Is ANG Lifesciences overvalued or undervalued?

As of August 16, 2024, ANG Lifesciences is considered risky and overvalued due to its negative PE ratio of -3.13, EV to EBITDA of -51.95, and poor financial performance, including a 41.32% decline in stock value over the past year compared to the Sensex's gain of 7.59%.

As of 16 August 2024, the valuation grade for ANG Lifesciences has moved from very attractive to risky, indicating a significant shift in its perceived value. The company appears to be overvalued based on its current metrics, with a PE ratio of -3.13, an EV to EBITDA of -51.95, and a ROE of -19.40%. These figures suggest that the company is struggling financially, which is further reflected in its negative returns over the past year and three years.<BR><BR>In comparison to its peers, ANG Lifesciences stands out with its negative PE ratio and EV to EBITDA, while other companies in the pharmaceuticals and biotechnology sector maintain positive valuations. For instance, if we consider a typical peer with a PE ratio around 15 and a more favorable EV to EBITDA, ANG Lifesciences clearly lags behind. Additionally, the stock has underperformed against the Sensex over the past year, with a decline of 41.32% compared to the index's gain of 7.59%. This reinforces the conclusion that ANG Lifesciences is currently overvalued.

What is the technical trend for ANG Lifesciences?

As of May 19, 2025, ANG Lifesciences shows a mildly bearish trend overall, with mixed signals from indicators like the weekly MACD being mildly bullish and daily moving averages indicating short-term weakness.

As of 19 May 2025, the technical trend for ANG Lifesciences has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD also shows mildly bullish. However, the daily moving averages are mildly bearish, suggesting short-term weakness. The Bollinger Bands on both weekly and monthly time frames are mildly bearish, reinforcing the cautious outlook. The KST is mildly bullish on the weekly but bearish on the monthly, indicating mixed signals. Overall, the current technical stance is mildly bearish, with key indicators such as the daily moving averages and Bollinger Bands driving this assessment.

Who are the peers of the ANG Lifesciences?

Peers of ANG Lifesciences include Sandu Pharma, Kabra Drugs, Roopa Industries, Chandra Bhagat, Veerhealth Care, Guj. Terce Labs, Mono Pharmacare, Medicamen Organ, and Vilin Bio Med. ANG Lifesciences has below-average management risk and capital structure, with a 1-year return of -38.19%, significantly lower than Kabra Drugs' 144.82%.

Peers: The peers of ANG Lifesciences are Sandu Pharma., Kabra Drugs, Roopa Industries, Chandra Bhagat, Veerhealth Care, Guj. Terce Labs., Mono Pharmacare, Medicamen Organ., and Vilin Bio Med.<BR><BR>Quality Snapshot: Below Average management risk is observed at Sandu Pharma., Roopa Industries, Chandra Bhagat, Veerhealth Care, ANG Lifesciences, Guj. Terce Labs., Mono Pharmacare, and Vilin Bio Med, while Average management risk is found at Medicamen Organ. Growth is classified as Excellent at Medicamen Organ., Good at Kabra Drugs and Mono Pharmacare, and Average at Guj. Terce Labs., while the rest have Below Average growth. Capital Structure is rated as Good for Sandu Pharma. and Veerhealth Care, while Below Average is noted for ANG Lifesciences, Roopa Industries, Chandra Bhagat, Guj. Terce Labs., Mono Pharmacare, Medicamen Organ., and Vilin Bio Med.<BR><BR>Return Snapshot: Kabra Drugs has the highest 1-year return at 144.82%, while ANG Lifesciences has the lowest at -38.19%. This shows that ANG Lifesciences' return is significantly lower than that of Kabra Drugs. Additionally, the six-month return is negative for ANG Lifesciences, Roopa Industries, Guj. Terce Labs., and Veerhealth Care.

Who are in the management team of ANG Lifesciences?

As of March 2022, the management team of ANG Lifesciences includes Rajesh Gupta (Managing Director), Saruchi Gupta (Whole Time Director & CFO), Sukhpal Singh, Sudesh Kumari, Pawanjit Singh, and Chetna (all Independent Directors), along with Renu (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

As of March 2022, the management team of ANG Lifesciences includes the following individuals:<BR><BR>1. Rajesh Gupta - Managing Director<BR>2. Saruchi Gupta - Whole Time Director & CFO<BR>3. Sukhpal Singh - Independent Director<BR>4. Sudesh Kumari - Director<BR>5. Pawanjit Singh - Independent Director<BR>6. Chetna - Independent Director<BR>7. Renu - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the top shareholders of the ANG Lifesciences?

The top shareholders of ANG Lifesciences include promoters, with Rajesh Gupta holding 70.41% of the shares, while individual investors own 26.11%. There are no mutual funds or foreign institutional investors currently involved.

The top shareholders of ANG Lifesciences are primarily the promoters, with Rajesh Gupta holding the highest stake at 70.41%. Additionally, individual investors collectively own 26.11% of the company. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in ANG Lifesciences.

How big is ANG Lifesciences?

As of 21st July, ANG Lifesciences India Ltd has a market capitalization of 41.00 Cr and reported Net Sales of 92.84 Cr with a Net Profit loss of 12.41 Cr for the latest four quarters. Shareholder's Funds were 76.28 Cr and Total Assets were 237.98 Cr as of March 2024.

As of 21st July, ANG Lifesciences India Ltd has a market capitalization of 41.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, ANG Lifesciences reported Net Sales of 92.84 Cr. However, the company experienced a Net Profit loss of 12.41 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, where Shareholder's Funds amounted to 76.28 Cr and Total Assets were reported at 237.98 Cr.

Are ANG Lifesciences latest results good or bad?

ANG Lifesciences' latest results show mixed signals; while the earnings per share improved to Rs -1.58, net sales plummeted by 55.55% year-on-year, leading to significant losses. The stock is rated as a 'Strong Sell' due to ongoing financial challenges.

ANG Lifesciences' latest results present a mixed picture. On one hand, the earnings per share (EPS) of Rs -1.58 indicates an improvement, as it is the highest EPS recorded in the last five quarters. However, the overall financial performance shows significant challenges. <BR><BR>Net sales for the quarter were Rs 16.82 crore, which is a substantial decline of 55.55% year-on-year, marking the lowest sales figure in the past five quarters. Additionally, profit before tax (PBT) fell sharply to Rs -4.54 crore, a decrease of 79.45% year-on-year, while profit after tax (PAT) also declined to Rs -2.06 crore, down 7.9% year-on-year.<BR><BR>Despite a slight improvement in the financial score from -14 to -9 over the past three months, the ongoing trends in sales and profitability suggest that ANG Lifesciences is still facing significant hurdles. The stock is currently rated as a 'Strong Sell', reflecting the market's concerns about the company's near-term outlook. Overall, while there are signs of some improvement in EPS, the broader financial results indicate a challenging environment for the company.

How has been the historical performance of ANG Lifesciences?

ANG Lifesciences has experienced a significant decline in net sales and profitability, with net sales dropping from INR 354.30 crore in March 2022 to INR 92.85 crore in March 2025, and profit after tax turning from a profit of INR 40.32 crore to a loss of INR 12.41 crore in the same period. The company's total assets and liabilities also decreased, and cash flow from operating activities fell to zero in March 2025.

Answer:<BR>The historical performance of ANG Lifesciences shows a significant decline in net sales and profitability over the past few years.<BR><BR>Breakdown:<BR>ANG Lifesciences experienced a decrease in net sales from INR 354.30 crore in March 2022 to INR 92.85 crore in March 2025. This downward trend is mirrored in total operating income, which fell from INR 354.30 crore in March 2022 to the same INR 92.85 crore in March 2025. The company's operating profit (PBDIT) also declined sharply, moving from a profit of INR 68.28 crore in March 2022 to a loss of INR 0.25 crore in March 2025. Profit before tax followed a similar trajectory, dropping from INR 53.50 crore in March 2022 to a loss of INR 15.70 crore in March 2025. Consequently, profit after tax also turned negative, going from a profit of INR 40.32 crore in March 2022 to a loss of INR 12.41 crore in March 2025. The company's total assets decreased from INR 286.75 crore in March 2022 to INR 223.22 crore in March 2025, while total liabilities also saw a reduction from INR 286.75 crore to INR 223.22 crore in the same period. Cash flow from operating activities has fluctuated, with a notable drop to zero in March 2025, compared to INR 26 crore in March 2023. Overall, ANG Lifesciences has faced significant challenges, reflected in its declining sales, profits, and cash flow over the years.

When is the next results date for ANG Lifesciences India Ltd?

ANG Lifesciences India Ltd will announce its results on 14 February 2026.

ANG Lifesciences India Ltd is scheduled to declare its results on 14 February 2026.

Should I buy, sell or hold ANG Lifesciences India Ltd?

Why is ANG Lifesciences India Ltd falling/rising?

As of 16-Mar, ANG Lifesciences India Ltd's stock price is declining at 22.22, down 2.03%, due to poor financial performance, significant operating losses, and a lack of investor interest, with a year-to-date drop of 24.81%. The company has consistently underperformed against benchmarks and faces challenges such as high debt levels and negative sales trends.

As of 16-Mar, ANG Lifesciences India Ltd is experiencing a decline in its stock price, currently at 22.22, which reflects a change of -0.46 or -2.03%. This downward movement can be attributed to several factors highlighted in the data. The stock has been underperforming significantly compared to the benchmark Sensex, with a 1-week decline of -3.39% and a 1-month drop of -11.30%. Year-to-date, the stock has fallen by -24.81%, while the Sensex has only decreased by -11.40%.<BR><BR>The stock has also shown a consistent pattern of decline, having fallen for three consecutive days, resulting in a total decrease of -4.8% during this period. Furthermore, ANG Lifesciences is trading below its moving averages across various time frames, indicating a bearish trend. The delivery volume has drastically decreased, with a -91.34% drop compared to the 5-day average, suggesting a lack of investor interest and participation.<BR><BR>Financially, the company is facing significant challenges, including operating losses and a weak long-term growth outlook, as evidenced by a -32.14% annual decline in net sales over the past five years and an alarming -167.45% in operating profit. The company's high debt-to-EBITDA ratio of 52.88 times raises concerns about its ability to service debt, further contributing to the stock's negative sentiment.<BR><BR>Additionally, the company has reported negative results for the last 15 consecutive quarters, with net sales falling by -24.26%. The high debt-equity ratio of 1.52 times and the lowest debtor turnover ratio of 1.06 times also indicate financial instability. The fact that 44.88% of promoter shares are pledged adds to the risk, as this can exert additional downward pressure on the stock price in a declining market.<BR><BR>Overall, the combination of poor financial performance, declining investor participation, and consistent underperformance against benchmarks has led to the current decline in ANG Lifesciences India Ltd's stock price.

Which are the latest news on ANG Lifesciences?